CLEC3B and ovarian carcinoma: Tetranectin binds to kringle 4 of plasminogen, enhancing the plasminogen activation by tissue-type plasminogen activator in the presence of poly-D-lysine [24] Low serum levels of tetranectin (CLEC3B) are associated with increased risk of second-line chemoresistance in patients with ovarian cancer [25].